Last reviewed · How we verify
TRTP-101
At a glance
| Generic name | TRTP-101 |
|---|---|
| Sponsor | CellinCells |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars (PHASE1, PHASE2)
- Long-Term Follow-up of Adult With Atorpphic Scars Treated With TRTP-101
- Safety and Tolerability of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRTP-101 CI brief — competitive landscape report
- TRTP-101 updates RSS · CI watch RSS
- CellinCells portfolio CI